ECSP099773A - Moduladores de gamma secretasa - Google Patents

Moduladores de gamma secretasa

Info

Publication number
ECSP099773A
ECSP099773A EC2009009773A ECSP099773A ECSP099773A EC SP099773 A ECSP099773 A EC SP099773A EC 2009009773 A EC2009009773 A EC 2009009773A EC SP099773 A ECSP099773 A EC SP099773A EC SP099773 A ECSP099773 A EC SP099773A
Authority
EC
Ecuador
Prior art keywords
compounds
methods
modulators
gamma
secretasa
Prior art date
Application number
EC2009009773A
Other languages
English (en)
Inventor
Zhaoning Zhu
Zhong-Yue Sun
William J Greenlee
Xianhai Huang
Ruo Xu
Xiaohong Zhu
Gioconda Gallo
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP099773A publication Critical patent/ECSP099773A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

En sus muchas realizaciones, la presente invención provee una clase novedosa de compuestos heterocíclicos como moduladores de gamma secretasa, métodos para preparar ese tipo de compuestos, composiciones farmacéuticas que contienen uno o más compuestos de ese tipo, métodos para preparar formulaciones farmacéuticas que comprenden uno o más compuestos de ese tipo, y métodos de tratamiento, prevención, inhibición o mejora de una o más enfermedades asociadas con el sistema nervioso central que utilizan dichos compuestos o composiciones farmacéuticas.
EC2009009773A 2007-06-01 2009-11-30 Moduladores de gamma secretasa ECSP099773A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94139607P 2007-06-01 2007-06-01

Publications (1)

Publication Number Publication Date
ECSP099773A true ECSP099773A (es) 2009-12-28

Family

ID=40130388

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009773A ECSP099773A (es) 2007-06-01 2009-11-30 Moduladores de gamma secretasa

Country Status (18)

Country Link
US (1) US8580956B2 (es)
EP (1) EP2164852A2 (es)
JP (1) JP2010529014A (es)
KR (1) KR20100021633A (es)
CN (1) CN101932578A (es)
AR (1) AR066151A1 (es)
AU (1) AU2008263206A1 (es)
BR (1) BRPI0812491A2 (es)
CA (1) CA2689930A1 (es)
CL (1) CL2008001559A1 (es)
CO (1) CO6241125A2 (es)
EC (1) ECSP099773A (es)
IL (1) IL202316A0 (es)
MX (1) MX2009013130A (es)
PE (1) PE20090319A1 (es)
RU (1) RU2009148865A (es)
TW (1) TW200904422A (es)
WO (1) WO2008153792A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0812170A8 (pt) 2007-06-01 2016-02-10 Schering Corp Moduladores de gama secretase
AU2009313538A1 (en) * 2008-11-06 2010-05-14 Merck Sharp & Dohme Corp. Gamma secretase modulators
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
AU2016214102B2 (en) 2015-02-03 2018-09-27 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2019151274A1 (ja) * 2018-02-01 2019-08-08 日本たばこ産業株式会社 含窒素複素環アミド化合物及びその医薬用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2659107B2 (ja) * 1991-03-28 1997-09-30 エーザイ株式会社 複素環式―環式アミン誘導体
WO2004071431A2 (en) 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
JP2007528857A (ja) 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
US20070293538A1 (en) 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
JP2007538024A (ja) 2004-05-19 2007-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
KR100966749B1 (ko) 2004-05-26 2010-06-30 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
JP5221144B2 (ja) * 2005-11-24 2013-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 モルホリンタイプ・シンナミド化合物
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound

Also Published As

Publication number Publication date
BRPI0812491A2 (pt) 2014-12-02
KR20100021633A (ko) 2010-02-25
EP2164852A2 (en) 2010-03-24
CL2008001559A1 (es) 2008-12-05
PE20090319A1 (es) 2009-03-27
US20100255005A1 (en) 2010-10-07
TW200904422A (en) 2009-02-01
IL202316A0 (en) 2010-06-30
AR066151A1 (es) 2009-07-29
WO2008153792A2 (en) 2008-12-18
AU2008263206A1 (en) 2008-12-18
CO6241125A2 (es) 2011-01-20
CA2689930A1 (en) 2008-12-18
MX2009013130A (es) 2010-01-15
WO2008153792A3 (en) 2009-05-07
CN101932578A (zh) 2010-12-29
AU2008263206A2 (en) 2010-01-21
RU2009148865A (ru) 2011-07-20
JP2010529014A (ja) 2010-08-26
US8580956B2 (en) 2013-11-12

Similar Documents

Publication Publication Date Title
ECSP099720A (es) Moduladores de gamma-secretasa
ECSP099776A (es) Moduladores de la gamma secretasa
MX2010001506A (es) Moduladores de gamma secretasa.
CL2016001364A1 (es) Moduladores de ror gamma (rory)
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CL2012001955A1 (es) Compuestos derivados biciclicos de triazol sustituidos, moduladores de gamma secretasa; composicion farmaceutica que los comprende; utiles en el tratamiento o la prevencion de enfermedad de alzheimer, demencia, demencia asociada con la enfermedad de parkinson, entre otras.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
GT201200220A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
CL2013000380A1 (es) Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion.
CL2011003350A1 (es) Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2012000752A1 (es) Compuestos derivados de fenilpiri(mi)dinilpirazoles para el control de microorganismos no deseados en la proteccion de plantas y compuestos intermediarios.
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
CL2008002876A1 (es) Compuestos derivados de heterociclo sustituidos, moduladores de gamma-secretasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades neurodegenerativas como alzheimer o sindrome de down.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
ECSP099773A (es) Moduladores de gamma secretasa
AR061637A1 (es) Composiciones y metodos de tratamiento de trastornos del snc
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
MX368635B (es) Compuestos tricíclicos de piperidina.
BR112015006727A8 (pt) uso de uma composição farmacêutica
CL2011000168A1 (es) Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer.